218 related articles for article (PubMed ID: 30487126)
1. Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study.
Peeters M; Price T; Boedigheimer M; Kim TW; Ruff P; Gibbs P; Thomas A; Demonty G; Hool K; Ang A
Clin Cancer Res; 2019 Feb; 25(4):1216-1225. PubMed ID: 30487126
[TBL] [Abstract][Full Text] [Related]
2. Impact of Emergent Circulating Tumor DNA
Kim TW; Peeters M; Thomas A; Gibbs P; Hool K; Zhang J; Ang AL; Bach BA; Price T
Clin Cancer Res; 2018 Nov; 24(22):5602-5609. PubMed ID: 29898991
[No Abstract] [Full Text] [Related]
3. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.
Siena S; Sartore-Bianchi A; Garcia-Carbonero R; Karthaus M; Smith D; Tabernero J; Van Cutsem E; Guan X; Boedigheimer M; Ang A; Twomey B; Bach BA; Jung AS; Bardelli A
Ann Oncol; 2018 Jan; 29(1):119-126. PubMed ID: 28945848
[TBL] [Abstract][Full Text] [Related]
4. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
[TBL] [Abstract][Full Text] [Related]
5. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
6. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
7. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
8. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
9. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
10. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
[TBL] [Abstract][Full Text] [Related]
11. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
[No Abstract] [Full Text] [Related]
13. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.
Price T; Ang A; Boedigheimer M; Kim TW; Li J; Cascinu S; Ruff P; Satya Suresh A; Thomas A; Tjulandin S; Peeters M
Cancer Biol Ther; 2020 Oct; 21(10):891-898. PubMed ID: 33026965
[TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
16. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.
El Messaoudi S; Mouliere F; Du Manoir S; Bascoul-Mollevi C; Gillet B; Nouaille M; Fiess C; Crapez E; Bibeau F; Theillet C; Mazard T; Pezet D; Mathonnet M; Ychou M; Thierry AR
Clin Cancer Res; 2016 Jun; 22(12):3067-77. PubMed ID: 26847055
[TBL] [Abstract][Full Text] [Related]
17. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Peeters M; Oliner KS; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD
Clin Cancer Res; 2015 Dec; 21(24):5469-79. PubMed ID: 26341920
[TBL] [Abstract][Full Text] [Related]
18. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
Li W; Qiu T; Guo L; Ying J
Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.
Yu H; Han L; Yuan J; Sun Y
Cancer Biomark; 2020; 27(1):29-37. PubMed ID: 31658042
[TBL] [Abstract][Full Text] [Related]
20. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.
Nicolazzo C; Barault L; Caponnetto S; De Renzi G; Belardinilli F; Bottillo I; Bargiacchi S; Macagno M; Grammatico P; Giannini G; Cortesi E; Di Nicolantonio F; Gazzaniga P
Cancer Lett; 2021 Jun; 507():89-96. PubMed ID: 33744389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
